Clearmind Medicine
Tracked across 2 events · 13 articles · First seen Jun 18, 2026 · Last active Aug 13, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Clearmind Medicine received two U.S. patents, strengthening its intellectual property portfolio for binge behavior regulators and advancing its clinical programs for related disorders. This enhances the company's market position and potential for commercialization.
Jun 18, 2026 · 7 articles
Business
Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotech company, announced that its independent Data and Safety Monitoring Board (DSMB) unanimously approved advancing its FDA-regulated Phase I/II clinical trial of CMND-100, a non-hallucinogenic neuroplastogen-derived candidate for…
Impact: Clearmind is the sponsor of the trial and the primary beneficiary of the DSMB approval, which advances its lead candidate CMND-100 into patient testing and supports its clinical development program.
Aug 06, 2026 · 6 articles
100
Clearmind Medicine received approvalClearmind DSMB Approves...
80
Clearmind Medicine completed Part AClearmind DSMB Approves...
ERGEN INTELLIGENCE
Track Clearmind Medicine live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard